Published in J Virol on August 01, 1997
Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol (2003) 3.76
How will HPV vaccines affect cervical cancer? Nat Rev Cancer (2006) 2.23
Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition. J Virol (2007) 2.05
Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J Virol (2003) 1.82
Characterization of a major neutralizing epitope on human papillomavirus type 16 L1. J Virol (1999) 1.52
Genetic Diversity in the Major Capsid L1 Protein of HPV-16 and HPV-18 in the Netherlands. PLoS One (2016) 1.39
L1 interaction domains of papillomavirus l2 necessary for viral genome encapsidation. J Virol (2001) 1.34
Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles. Proc Natl Acad Sci U S A (1999) 1.31
A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study. J Infect Dis (2011) 1.31
Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1. J Virol (2003) 1.27
Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera. J Virol (2006) 1.20
Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16. J Virol (2003) 1.11
Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles. Virology (2007) 1.07
Chimeric papillomavirus-like particles expressing a foreign epitope on capsid surface loops. J Gen Virol (2001) 1.05
Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity. Virol J (2012) 1.04
Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol (2009) 1.02
Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer. J Virol (2005) 1.00
Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers. J Virol (2005) 0.98
Bovine papillomavirus type 1 (BPV1) and BPV2 are closely related serotypes. Virology (2009) 0.98
Maturation of the human papillomavirus 16 capsid. MBio (2014) 0.97
Multiscale simulation of microbe structure and dynamics. Prog Biophys Mol Biol (2011) 0.96
Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33. Virol J (2006) 0.95
Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine. Vaccine (2010) 0.94
Prevalence of human papillomavirus genotypes and their variants in high risk West Africa women immigrants in South Italy. Infect Agent Cancer (2007) 0.92
Efficient production of chimeric human papillomavirus 16 L1 protein bearing the M2e influenza epitope in Nicotiana benthamiana plants. BMC Biotechnol (2011) 0.91
Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals. Mol Cell Probes (2012) 0.90
Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity. J Virol (2009) 0.89
Identification of B-cell epitopes on virus-like particles of cutaneous alpha-human papillomaviruses. J Virol (2009) 0.87
Characterization of HPV16 L1 loop domains in the formation of a type-specific, conformational epitope. BMC Microbiol (2004) 0.85
Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines. Infect Genet Evol (2013) 0.80
Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins. Hum Vaccin Immunother (2015) 0.79
The U4 Antibody Epitope on Human Papillomavirus 16 Identified by Cryo-electron Microscopy. J Virol (2015) 0.78
Cleavage of the HPV16 Minor Capsid Protein L2 during Virion Morphogenesis Ablates the Requirement for Cellular Furin during De Novo Infection. Viruses (2015) 0.78
A human monoclonal antibody against HPV16 recognizes an immunodominant and neutralizing epitope partially overlapping with that of H16.V5. Sci Rep (2016) 0.76
Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV). PLoS One (2017) 0.75
Evidence for Placental HPV Infection in Both HIV Positive and Negative Women. J Cancer Ther (2015) 0.75
Efficient Production of Papillomavirus Gene Delivery Vectors in Defined In Vitro Reactions. Mol Ther Methods Clin Dev (2017) 0.75
Crystal Structures of Two Immune Complexes Identify Determinants for Viral Infectivity and Type-Specific Neutralization of Human Papillomavirus. MBio (2017) 0.75
Naturally occurring capsid protein variants L1 of human papillomavirus genotype 16 in Morocco. Bioinformation (2017) 0.75
Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst (1995) 18.86
Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A (1992) 7.72
A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (N Y) (1991) 7.08
Human papillomaviruses in the pathogenesis of anogenital cancer. Virology (1991) 5.74
Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol (1993) 5.12
Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A (1995) 4.15
Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol (1995) 4.14
Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction. Biophys J (1991) 4.07
In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol (1996) 3.66
Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis (1995) 3.25
Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer (1993) 3.13
Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology (1996) 2.83
Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr Top Microbiol Immunol (1994) 2.52
Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins. J Virol (1994) 2.52
Interaction of papillomaviruses with the cell surface. J Virol (1994) 2.44
Antibody-mediated neutralization in vivo of infectious papillomaviruses. J Virol (1990) 2.34
Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11. J Virol (1990) 2.26
Papillomavirus capsid binding and uptake by cells from different tissues and species. J Virol (1995) 2.24
Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. J Virol (1995) 2.13
Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology (1996) 2.08
Identification of proteins encoded by the L1 and L2 open reading frames of human papillomavirus 1a. J Virol (1987) 2.01
Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol (1996) 1.94
Three-dimensional structure of vaccinia virus-produced human papillomavirus type 1 capsids. J Virol (1994) 1.70
Binding and internalization of human papillomavirus type 33 virus-like particles by eukaryotic cells. J Virol (1995) 1.70
Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. Virology (1994) 1.64
Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles. J Gen Virol (1994) 1.60
Production and characterisation of a monoclonal antibody to human papillomavirus type 16 using recombinant vaccinia virus. J Clin Pathol (1990) 1.57
Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor. J Virol (1995) 1.32
Two amino acid residues confer type specificity to a neutralizing, conformationally dependent epitope on human papillomavirus type 11. J Virol (1996) 1.29
Neutralization of CRPV infectivity by monoclonal antibodies that identify conformational epitopes on intact virions. Virus Res (1991) 1.19
Divergent human papillomavirus type 16 variants are serologically cross-reactive. J Infect Dis (1995) 1.17
Monoclonal antibody neutralization of BPV-1. Virus Res (1993) 1.08
Papillomavirus vaccines: current status and future prospects. Adv Dermatol (1996) 0.99
Sequence variation in the capsid protein genes of human papillomavirus type 16 and type 31. Virology (1995) 0.95
Mechanism of activation of a human oncogene. Nature (1982) 12.09
Mouse cells transformed by bovine papillomavirus contain only extrachromosomal viral DNA sequences. Proc Natl Acad Sci U S A (1981) 9.27
Murine leukemia virus: high-frequency activation in vitro by 5-iododeoxyuridine and 5-bromodeoxyuridine. Science (1971) 8.78
Natural history of acute coronary heart attacks. A community study. Br Heart J (1972) 8.55
The p21 src genes of Harvey and Kirsten sarcoma viruses originate from divergent members of a family of normal vertebrate genes. Nature (1981) 8.44
Helper-independent transformation by unintegrated Harvey sarcoma virus DNA. J Virol (1978) 7.75
Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A (1992) 7.72
A quantitative in vitro focus assay for bovine papilloma virus. Virology (1980) 7.14
In vitro tumorigenic transformation by a defined sub-genomic fragment of bovine papilloma virus DNA. Nature (1980) 6.67
HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J (1989) 6.60
Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med (2001) 6.33
Identification of a second transforming region in bovine papillomavirus DNA. Proc Natl Acad Sci U S A (1984) 5.88
RANK is essential for osteoclast and lymph node development. Genes Dev (1999) 5.85
Bovine papillomavirus E2 trans-activating gene product binds to specific sites in papillomavirus DNA. Nature (1987) 5.61
Analysis of two divergent rat genomic clones homologous to the transforming gene of Harvey murine sarcoma virus. Proc Natl Acad Sci U S A (1981) 5.51
Cellular origin and role of mink cell focus-forming viruses in murine thymic lymphomas. Nature (1982) 5.23
Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol (1993) 5.12
Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus. Nature (1982) 5.08
Transfection of molecularly cloned Friend murine leukemia virus DNA yields a highly leukemogenic helper-independent type C virus. J Virol (1980) 4.91
Molecular cloning of infectious integrated murine leukemia virus DNA from infected mouse cells. Proc Natl Acad Sci U S A (1980) 4.71
Dual evolutionary origin for the rat genetic sequences of Harvey murine sarcoma virus. J Virol (1980) 4.63
Origin of mink cytopathic focus-forming (MCF) viruses:comparison with ecotropic and xenotropic murine leukemia virus genomes. Virology (1981) 4.62
Guanosine triphosphatase activating protein (GAP) interacts with the p21 ras effector binding domain. Science (1988) 4.58
Virus-specific transcription in bovine papillomavirus-transformed mouse cells. Virology (1982) 4.52
Qualitative and quantitative studies of AKR-type murine leukemia virus sequences in mouse DNA. Cold Spring Harb Symp Quant Biol (1975) 4.49
The p21 ras C-terminus is required for transformation and membrane association. Nature (1984) 4.43
Harvey murine sarcoma virus p21 ras protein: biological and biochemical significance of the cysteine nearest the carboxy terminus. EMBO J (1984) 4.28
Structure of endogenous murine leukemia virus DNA in mouse genomes. Proc Natl Acad Sci U S A (1980) 4.24
Genomes of murine leukemia viruses isolated from wild mice. J Virol (1981) 4.24
Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol (1995) 4.14
Long terminal repeat of murine retroviral DNAs: sequence analysis, host-proviral junctions, and preintegration site. J Virol (1982) 4.06
E5 open reading frame of bovine papillomavirus type 1 encodes a transforming gene. J Virol (1986) 4.04
A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst (1994) 3.95
Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene. Science (1987) 3.93
Molecular cloning of the Harvey sarcoma virus closed circular DNA intermediates: initial structural and biological characterization. J Virol (1979) 3.90
In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol (1996) 3.66
Virus infection of murine teratocarcinoma stem cell lines. Cell (1977) 3.54
Definitive evidence that the murine C-type virus inducing locus Akv-1 is viral genetic material. Proc Natl Acad Sci U S A (1975) 3.51
Human genome contains four genes homologous to transforming genes of Harvey and Kirsten murine sarcoma viruses. Proc Natl Acad Sci U S A (1982) 3.48
Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell (1992) 3.30
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst (2001) 3.28
Characterization of a human colon/lung carcinoma oncogene. Nature (1983) 3.26
Identification of the protein encoded by the E6 transforming gene of bovine papillomavirus. Science (1985) 3.21
The transforming function of bovine papillomavirus DNA. Proc Natl Acad Sci U S A (1983) 3.19
Translation of open reading frame E5 of bovine papillomavirus is required for its transforming activity. Proc Natl Acad Sci U S A (1986) 3.17
Mammalian and yeast ras gene products: biological function in their heterologous systems. Science (1985) 3.03
Papillomavirus polypeptides E6 and E7 are zinc-binding proteins. J Virol (1989) 3.01
Evidence that the AKR murine-leukemia-virus genome is complete in DNA of the high-virus AKR mouse and incomplete in the DNA of the "virus-negative" NIH mouse. Proc Natl Acad Sci U S A (1974) 2.95
AKR murine leukemia virus genome: frequency of sequences in DNA of high-, low-, and non-virus-yielding mouse strains. Proc Natl Acad Sci U S A (1974) 2.91
Nucleotide sequence of the 3' end of MCF 247 murine leukemia virus. J Virol (1983) 2.87
Identification of the HPV-16 E6 protein from transformed mouse cells and human cervical carcinoma cell lines. EMBO J (1987) 2.84
Mutational analysis of a ras catalytic domain. Mol Cell Biol (1986) 2.76
The specific DNA recognition sequence of the bovine papillomavirus E2 protein is an E2-dependent enhancer. EMBO J (1988) 2.66
Human keratinocytes are a source for tumor necrosis factor alpha: evidence for synthesis and release upon stimulation with endotoxin or ultraviolet light. J Exp Med (1990) 2.62
The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. EMBO J (1990) 2.57
The bovine papillomavirus E5 transforming protein can stimulate the transforming activity of EGF and CSF-1 receptors. Cell (1989) 2.52
Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins. J Virol (1994) 2.52
Functional organization of the Harvey murine sarcoma virus genome. J Virol (1980) 2.46
Interaction of papillomaviruses with the cell surface. J Virol (1994) 2.44
The E7 open reading frame of human papillomavirus type 16 encodes a transforming gene. Oncogene Res (1988) 2.42
High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev (2001) 2.38
Novel structural features of bovine papillomavirus capsid revealed by a three-dimensional reconstruction to 9 A resolution. Nat Struct Biol (1997) 2.30
Bovine papilloma virus-transformed cells contain multiple E2 proteins. Proc Natl Acad Sci U S A (1988) 2.29
Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol (2001) 2.28
Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology (2000) 2.25
Restriction endonuclease mapping of ecotropic murine leukemia viral DNAs: size and sequence heterogeneity of the long terminal repeat. Virology (1981) 2.25
Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia. J Infect Dis (1995) 2.21
The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis (1996) 2.21